1247003-32-2Relevant articles and documents
The discovery of polo-like kinase 4 inhibitors: Identification of (1 R,2 S)-2-(3-((E)-4-(((cis)-2,6-Dimethylmorpholino)methyl)styryl)-1 H -indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a potent, orally active antitumor agent
Sampson, Peter B.,Liu, Yong,Forrest, Bryan,Cumming, Graham,Li, Sze-Wan,Patel, Narendra Kumar,Edwards, Louise,Laufer, Radoslaw,Feher, Miklos,Ban, Fuqiang,Awrey, Donald E.,Mao, Guodong,Plotnikova, Olga,Hodgson, Richard,Beletskaya, Irina,Mason, Jacqueline M.,Luo, Xunyi,Nadeem, Vincent,Wei, Xin,Kiarash, Reza,Madeira, Brian,Huang, Ping,Mak, Tak W.,Pan, Guohua,Pauls, Henry W.
supporting information, p. 147 - 169 (2015/03/03)
Previous publications from our laboratory have introduced novel inhibitors of Polo-like kinase 4 (PLK4), a mitotic kinase identified as a potential target for cancer therapy. The search for potent and selective PLK4 inhibitors yielded (E)-3-((1H-indazol-6-yl)methylene)indolin-2-ones, which were superseded by the bioisosteric 2-(1H-indazol-6-yl)spiro[cyclopropane-1,3′-indolin]-2′-ones, e.g., 3. The later scaffold confers improved drug-like properties and incorporates two stereogenic centers. This work reports the discovery of a novel one-pot double SN2 displacement reaction for the stereoselective installation of the desired asymmetric centers and confirms the stereochemistry of the most potent stereoisomer, e.g., 44. Subsequent work keys on the optimization of the oral exposure of nanomolar PLK4 inhibitors with potent cancer cell growth inhibitory activity. A short list of compounds with superior potency and pharmacokinetic properties in rodents and dogs was studied in mouse models of tumor growth. We conclude with the identification of compound 48 (designated CFI-400945) as a novel clinical candidate for cancer therapy.
KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
-
Page/Page column 196, (2010/11/03)
The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
